NCT00568815View on ClinicalTrials.gov

Rituximab Combined With ESHAP in Patients With Relapse or Refractory Diffuse Large B Cell Lymphoma (DLBCL)

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions
Lymphoma
Interventions
DRUG

Rituximab combined with ESHAP

Rituximab 375mg/m2 d1, VP-16 40mg/m2 d1-4, Ara-C 2g/m2 d5, DDP 25mg/m2 d1-4, Met 500mg/m2 d1-5

Trial Locations (1)

200032

Fudan University Cancer Hospital, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER

NCT00568815 - Rituximab Combined With ESHAP in Patients With Relapse or Refractory Diffuse Large B Cell Lymphoma (DLBCL) | Biotech Hunter | Biotech Hunter